Cipla to make version of Relenza for Indian market

02/21/2006 | Business Standard (India)

India's Cipla announced it will manufacture zanamivir, currently sold by GlaxoSmithKline under the name Relenza. GSK recently received permission to import the anti-flu drug to India, but a GSK official said its European production capacity may not be sufficient in the short term and licensing of the drug to other firms has not been decided.

View Full Article in:

Business Standard (India)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX